2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
dacetuzumab
2
Antineoplastic Agents
2
ficlatuzumab
1
Vorinostat
1
Vitamin E
1
Tinzaparin
1
Plastic Surgery Procedures
1
Lenalidomide
1
Erlotinib Hydrochloride
1
Dexamethasone
1
Calcium Dobesilate
1
Bortezomib
1
Blood Specimen Collection
1
Aspirin
1
ARQ531
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vascular Diseases
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled